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Innovative In Vitro Chemo-Hormonal Drug Therapy for 
Refractory Thyroid Carcinomas 
More than 95% of the thyroid carcinomas are well differentiated types showing favorable 
prognosis. However, only a few therapeutic options are available to treat the patients with 
undifferentiated thyroid carcinomas, especially with refractory thyroid carcinomas that are 
not amenable to surgery or radioiodine ablation. We investigated the anticancer effects of 
20 chemotherapy and hormonal therapy drugs on 8 thyroid carcinoma cell lines. In vitro 
chemosensitivity was tested using the adenosine-triphosphate-based chemotherapy 
response assay (ATP-CRA). The tumor inhibition rate (TIR; or cell death rate) or half 
maximal inhibitory concentration (IC50) was analyzed to interpret the results. Of the 12 
chemotherapy drugs, etoposide (178.9 index value in follicular carcinoma cell line) and 
vincristine (211.7 in Hürthle cell carcinoma cell line) were the most active drugs showing 
the highest chemosensitivity, and of the 8 additional drugs, trichostatin A (0.03 µg/mL IC50 
in follicular carcinoma cell line) showed favorable outcome having the anticancer effect. In 
our study, the result of etoposide and vincristine show evidence as active anticancer drugs 
in thyroid carcinoma cell lines and trichostatin A seems be the next promising drug. These 
drugs may become an innovative therapy for refractory thyroid carcinomas in near future.
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INTRODUCTION
In general, thyroid carcinomas can be classified as well differ-
entiated thyroid carcinomas having favorable prognoses, and 
undifferentiated thyroid carcinomas having poor prognoses (1). 
Fortunately, more than 95% of the thyroid carcinomas are well 
differentiated types, including papillary thyroid carcinoma (PTC), 
follicular thyroid carcinoma (FTC), and their related variant 
types. However, the remaining 5% which includes anaplastic 
thyroid carcinoma (ATC), poorly differentiated types, and para-
follicular C cell origin medullary thyroid carcinoma (MTC), show 
unfavorable disease processes despite an aggressive therapy (2).
 For thyroid carcinomas, surgery with thyroid stimulating hor-
mone (TSH) suppression and radioiodine ablation (RIA) is the 
most effective therapy. In general, well differentiated thyroid 
carcinomas such as PTC and FTC show excellent prognoses 
after the surgery with the combination of RIA according to the 
disease stage and many patients experience a curative or indo-
lent clinical course (3). Also, the prognosis after a local recurrence 
or distant metastasis for most of the well differentiated thyroid 
carcinomas are well controlled under the adequate re-opera-
tion or RIA (4).
 About 5% of the thyroid carcinoma is classified as undifferen-
tiated type and although rare, ATC and MTC are usually resis-
tant to the standard thyroid carcinoma treatment. At the time 
of diagnosis, ATC is usually unresectable, RIA resistant; and ex-
ternal radiation therapy has been used with no definite clinical 
survival benefits (5, 6). Postoperative RIA has no effect on MTC 
which is parafollicular C cell origin (7, 8). Likewise, such lack of 
treatment modality is even worse especially with patients hav-
ing refractory thyroid carcinomas. The refractory thyroid carci-
nomas could be defined as not amenable to surgery or RIA, io-
dine-refractory metastatic thyroid carcinomas, or which RIA is 
not an appropriate therapy from the beginning (9, 10). To over-
come these problems, many institutions are investigating to find 
a new treatment modality for refractory thyroid carcinoma fo-
cused on the combination of drug chemotherapy, hormonal 
therapy and molecular targeted therapy (9, 11).
 Previous studies about chemotherapy drugs for refractory thy-
roid carcinomas include doxorubicin, cisplatin, vincristine, cy-
clophosphamide, epirubicin and 5-fluorouracil (7, 12-14). Doxo-
rubicin has been the most widely investigated drug analyzed for 
anticancer effect either by itself or in combination regimens (15). 
However, such studies were performed only on few patients and 
yielded unsatisfactory results, with best of the results showing 
either limited partial response or stable disease status (8).
Sung T-Y, et al. • Drugs for Refractory Thyroid Carcinoma
730  http://jkms.org http://dx.doi.org/10.3346/jkms.2012.27.7.729
 Due to these unsatisfactory outcomes, many studies about 
the etiology and oncogenic mutations of refractory thyroid car-
cinomas are underway, with the latter including mutations in 
the BRAF, RAS, and RET/PTC genes (16, 17). In addition, drugs 
with different mechanisms have been developed mostly target-
ed at vascular endothelial growth factor (VEGF), platelet-de-
rived growth factor (PDGF) and tyrosine-kinase inhibitors (15, 
18, 19). To test these targeted drugs and to find an innovative 
drug therapy for refractory thyroid carcinomas, we have tested 
the effects of 20 drugs on 8 thyroid carcinoma cell lines.
MATERIALS AND METHODS
Cell culture
We cultured 8 thyroid carcinoma cell lines, 1 papillary (TPC-1), 
4 follicular (WRO, FTC133, FTC236 and FTC238), 1 Hürthle cell 
(XTC-1), 1 medullary (TT) and 1 anaplastic (FRO), all of which 
were purchased from American Type Culture Collection (Manas-
sas, VA, USA) and all were originated from known tumors with-
out laboratory cross-contamination (20). TPC-1, FTC133, FTC236, 
FTC238, XTC-1, and TT cells were cultured by Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 100 U/mL penicillin, 100 µg/mL strepto-
mycin and D-glucose. WRO and FRO cells were cultured by 
Roswell Park Memorial Institute (RPMI) medium supplement-
ed with 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomy-
cin, 25 mM HEPES, and L-glutamine.
Chemotherapy and hormonal therapy drugs
The 12 well acknowledged chemotherapy drugs tested were 
5-fluorouracil (5-FU), bleomycin, carboplatin, cisplatin, cyclo-
phosphamide, doxorubicin, epirubicin, etoposide, methotrex-
ate, oxaliplatin, paclitaxel, and vincristine. They were selected 
for their known anticancer effect and cytotoxicity for other ma-
lignancies, and that they have been previously studied on thy-
roid carcinomas. 
 The 8 additional chemotherapy and hormonal therapy drugs 
tested were quercetin, resveratrol, rosiglitazone, sunitinib, tamox-
ifen, trichostatin A, valproic acid, and vandetanib. They were 
selected because their anticancer effect on other malignancies, 
especially breast carcinoma, has been reported but not clearly 
tested for thyroid carcinoma and some, not yet in clinical trial. 
The vandetanib drug was donated donated by AstraZeneca UK 
Limited and all other drugs were obtained from ISU ABXIS Co., 
Ltd. in Yonsei University Medical Center, Korea.
Evaluation of in vitro chemosensitivity
The cells were plated at 6000 cells per well in 96 well plates (Nun-
clon, Roskilde, Denmark) and cultured for 24 hr. Drugs were 
added to each well and incubated with the cells for 48 hr before 
the chemosensitivity test. The assay used to test the chemosen-
sitivity was adenosine-triphosphate-based chemotherapy re-
sponse assay (ATP-CRA) (21).
 ATP is the basic energy source of all live cells and rapidly de-
creases with cell death. Cells from the treated and untreated con-
trol groups were lysed and the amount of ATP in the lysated cell 
was measured using flash type luminescence measurements 
on a Victor 3 multilabel counter (PerkinElmer, Boston, MA, USA). 
The cell death rate for each drug was defined as the rate of ATP 
luminescence reduction in the treated group compared with 
the untreated control (21). The increase in ATP reduction would 
mean better anti-cancer effect. By doing so, the tumor growth 
inhibition or cell death was compared between the drug treated 
cells and untreated control cells.
 For the 12 well acknowledged chemotherapy drugs, we per-
formed 3 test drug concentrations (TDC) (21-23) at 20%, 100%, 
and 500% to calculate the chemosensitivity (23) and the appli-
cation continued for a maximum of 6 cycles or until the reduc-
tion was reproducible within the error range. Tumor inhibition 
rate (TIR; or cell death rate) was calculated by measuring the 
reduction in ATP luminescence and compare with untreated 
control cell; and the drug was defined as an active drug when 
TDC resulted in more than 30% TIR (21). To calculate the TIR 
index value, the sum of TIR (20%-500% TDC) was subtracted 
from 300, and this index value was used to rank the tested drugs 
which a lower value indicated a more active drug. The results of 
the 8 index values for each drug were averaged to calculate the 
mean index values. The cut-off mean TIR index value for deter-
mining more active drug was set at 100 for our study.
 To evaluate the chemosensitivity of additional 8 drugs, we 
used the half maximal inhibitory concentration (IC50) (24). The 
IC50 is a function antagonist assay which measures the effective-
ness of a compound in inhibiting the biological or biochemical 
function. The IC50 of each drug was determined using the regres-
sion equation (Sigma Plot, San Jose, CA, USA), y = min + (max-
min)/(1 + (x/EC50)Hill slope) and the lower value indicated a more 
active drug. Since the optimal drug doses for a recognizable ac-
tivity against the thyroid carcinoma cell lines have not been clar-
ified, the inhibition dependent dose ranges were obtained from 
nine different dose response curve, using cells treated with 1.875-
300 µg/mL quercetin (25, 26), 0.39-800 µg/mL resveratrol (27), 
0.75-192 µg/mL rosiglitazone (28), 0.0002-200 µg/mL sunitinib 
(29), 0.11-30 µg/mL tamoxifen (30), 0.00469-1.2 µg/mL tricho-
statin A (31), 777.6-2000 µg/mL valproic acid (32), and 0.039-60 
µg/mL vandetanib (33). Recently, the studies about sunitinib 
and vandetanib are actively investigated by many other institu-
tions (34).
 
RESULTS
Well acknowledged chemotherapy drugs
Three TDCs (20%, 100%, and 500%) of 12 well acknowledged 
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chemotherapy drugs were individually applied to 8 thyroid car-
cinoma cell lines to measure the TIR (Table 1). The mean TIR 
was calculated to analyze those drugs showing more than 30% 
TIR in cell lines (data not shown). From 100% TDC results, we 
Table 1. The tumor inhibition rate of 12 well acknowledged chemotherapy drugs at 3 test drug concentrations
Drugs
Tumor inhibition rate
TDC % TPC-1 WRO FTC 133 FTC 236 FTC 238 XTC-1 TT FRO
5-FU 20
100
500
41.5 
74.1 
77.6 
43.0 
68.7 
77.9 
44.8 
61.2 
75.7 
32.0 
36.8 
54.1 
50.2 
66.4 
79.1 
15.5 
26.9 
50.9 
0.0 
14.2 
43.7 
60.5 
74.7 
89.2 
Bleomycin 20
100
500
17.4 
19.1 
30.3 
0.0 
0.0 
0.0 
60.0 
82.8 
93.4 
9.8 
23.1 
35.8 
22.1 
37.0 
64.0 
44.2 
20.1 
4.4 
20.5 
29.1 
38.1 
24.8 
52.8 
85.9 
Carboplatin 20
100
500
2.5 
0.0 
32.1 
0.0 
1.6 
52.1 
8.2 
22.3 
92.4 
4.8 
20.8 
84.5 
12.7 
35.9 
92.8 
9.7 
33.3 
75.2 
14.6 
22.5 
51.3 
7.7 
87.1 
78.3 
Cisplatin 20
100
500
7.8 
5.3 
70.5 
0.2 
31.0 
67.3 
12.2 
38.6 
91.0 
9.1 
35.6 
81.5 
17.6 
64.3 
93.7 
23.5 
36.1 
70.7 
0.0 
0.0 
30.3 
8.1 
38.1 
93.8 
CP 20
100
500
7.6 
9.4 
29.8 
0.0 
3.7 
22.0 
2.1 
8.2 
69.0 
9.0 
15.8 
41.4 
9.3 
17.0 
80.2 
0.0 
8.9 
99.3 
0.0 
0.3 
81.1 
10.3 
14.1 
94.8 
Doxorubicin 20
100
500
7.2 
46.1 
82.3 
0.0 
15.7 
54.4 
23.5 
51.1 
81.9 
23.1 
62.8 
73.6 
17.9 
52.8 
80.5 
7.1 
10.5 
53.1 
21.4 
36.2 
36.2 
19.7 
49.4 
81.5 
Epirubicin 20
100
500
18.2 
39.0 
86.6 
10.4 
24.9 
55.5 
25.2 
47.0 
80.4 
21.0 
62.1 
72.8 
22.1 
59.1 
79.2 
44.2 
29.4 
62.3 
5.0 
24.1 
24.7 
31.5 
60.4 
86.0 
Etoposide 20
100
500
21.2 
68.0 
97.8 
0.5 
47.9 
72.7 
69.9 
90.2 
95.3 
74.1 
89.5 
89.8 
61.6 
83.3 
89.2 
38.7 
65.7 
74.1 
20.4 
26.9 
97.8 
65.8 
92.5 
88.7 
MTX 20
100
500
51.4 
59.0 
78.5 
52.0 
54.9 
64.6 
66.4 
75.6 
91.5 
70.0 
75.7 
88.6 
78.7 
82.0 
90.5 
19.2 
23.2 
57.1 
0.0 
7.4 
49.0 
83.6 
86.8 
93.1 
Oxaliplatin 20
100
500
21.3 
25.2 
31.4 
41.1 
62.6 
65.6 
31.2 
40.4 
70.5 
31.0 
43.6 
84.1 
37.8 
43.3 
88.8 
13.7 
20.6 
69.7 
33.5 
80.5 
42.6 
30.3 
38.0 
76.1 
Paclitaxel 20
100
500
98.3 
67.3 
87.5 
52.9 
56.9 
84.7 
80.5 
73.1 
89.1 
64.9 
59.9 
75.9 
75.7 
54.3 
59.1 
0.0 
10.0 
0.0 
0.1 
0.0 
83.0 
86.8 
38.1 
93.9 
Vincristine 20
100
500
9.1 
93.8 
95.3 
62.7 
61.7 
61.2 
81.6 
83.9 
86.9 
47.0 
49.1 
50.8 
83.7 
83.9 
85.2 
28.0 
29.8 
30.5 
60.8 
82.6 
88.0 
70.7 
70.5 
71.6 
TDC, test drug concentration; 5-FU, 5-fluorouracil; CP, cyclophosphamide; MTX, methotrexate.
Fig. 1. The mean tumor inhibition rate index values of 12 well acknowledged chemotherapy drugs. The lowest mean index values were seen in etoposide and vincristine sug-
gesting that these drugs are more active than others.
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found that etoposide, vincristine and methotrexate, and 5-FU 
were the most active drugs, whereas cyclophosphamide the 
least active. Although drugs had a more than 30% TIR at 500% 
TDC, this concentration would be beyond clinical application. 
Even though all TIR did not increase in uniform pattern accord-
ing to the TDC, we found that 5-FU, etoposide, methotrexate 
and vincristine showed a linear increase in TIR.
 Then, we determined the TIR index value for each drug at 
3 TDCs (Fig. 1). The mean TIR index values of 3 TDCs showed 
that vincristine and etoposide had the lowest values than the 
other drugs suggesting that these 2 drugs were more active in 
inhibiting thyroid carcinoma all growth. In contrast, cyclophos-
phamide was observed as inactive. Next, we compared the mean 
TIR index values according to the types of thyroid carcinoma 
cell lines: papillary, follicular, Hürthle cell, medullary and ana-
plastic (Fig. 2). In this figure, paclitaxel and vincristine showed 
as most active drugs when cut-off mean index value set at 100. 
Etoposide, methotrexate, paclitaxel, and vincristine showed 
similar index values for follicular cell lines in general. 
 When these results were individualized by each cell lines, 
vincristine had the lowest index value of 19.8 in papillary TPC-1 
cell. Also, paclitaxel showed favorable activity of 46.9. In follicu-
lar cell lines, etoposide and methotrexate showed potent activity 
in FTC133, FTC236, and FTC238. Vincristine was the only active 
drug in medullary TT cell; and 5-FU, etoposide, methotrexate, 
paclitaxel, and vincristine showed activity in anaplastic FRO cell. 
Unfortunately, none of the tested drugs inhibited the growth of 
Hürthle cell line, XTC-1 (Table 2).
Additional chemotherapy and hormonal therapy drugs
We tested the chemosensitivity of the 8 additional chemothera-
py and hormonal therapy drugs which were not well tested for 
thyroid carcinoma cell lines previously. The drugs were tested 
by determining their IC50 values to each cell line and we found 
Table 2. The tumor inhibition rate index values of 12 well acknowledged chemotherapy drugs at 3 concentrations applied to 8 thyroid carcinoma cell lines analyzed according 
to the types of thyroid carcinoma cell lines
Drugs
Index value
TPC-1 WRO FTC133 FTC236 FTC238 XTC-1 TT FRO
5-FU 106.8 110.4 118.3 177.1 104.3 206.7 242.1 75.6 
Bleomycin 233.2 300.0 63.8 231.3 177.0 231.3 212.3 136.5 
Carboplatin 265.4 246.3 177.1 189.9 158.6 181.8 211.6 191.3 
Cisplatin 216.4 201.5 158.2 173.8 124.4 169.7 269.7 160.0 
CP 253.2 274.3 220.7 233.8 193.5 191.8 218.6 180.8 
Doxorubicin 164.4 229.9 143.5 140.5 148.8 229.3 206.2 149.4 
Epirubicin 156.2 209.2 147.4 144.1 139.6 164.1 246.2 122.1 
Etoposide 113.0 178.9 44.6 46.6 65.9 121.5 154.9 53.0 
MTX 111.1 128.5 66.5 65.7 48.8 200.5 243.6 36.5 
Oxaliplatin 222.1 130.7 157.9 141.3 130.1 196.0 143.4 151.8 
Paclitaxel 46.9 105.5 57.3 99.3 110.9 300.0 216.9 32.2 
Vincristine 19.8 114.4 47.6 153.1 47.2 211.7 68.6 87.2 
Index value, 300 - [sum of tumor inhibition rate at 3 test drug concentrations]; 5-FU, 5-fluorouracil; CP, cyclophosphamide; MTX, methotrexate.
Fig. 2. The mean tumor inhibition rate index values of 12 well acknowledged chemotherapy drugs applied to 8 thyroid carcinoma cell lines analyzed according to the types of 
thyroid carcinoma cell lines. Follicular cell lines data shown are the mean value of 4 cell lines.
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Table 3. The half maximal inhibitory concentration (IC50) of 8 additional chemotherapy and hormonal therapy drugs
Drugs
IC50
Range (µg/mL) TPC-1 WRO FTC 133 FTC 236 FTC 238 XTC-1 TT  FRO
Quercetin 1.875-300 114.00 24.36 100.39 93.93 57.88 95.51 107.65 40.42
Resveratrol 0.39-800 66.64 31.90 48.24 48.37 37.52 94.94 63.18 46.24
Rosiglitazone 0.75-192 47.71 120.80 140.32 33.31 43.60 86.94 95.06 115.01
Sunitinib 0.0002-200 6.31 17.65 29.00 18.42 22.97 53.22 7.92 7.15
Tamoxifen 0.11-30 20.59 21.86 23.09 16.42 20.13 18.16 26.21 18.21
Trichostatin A 0.00469-1.2 0.06 0.03 0.05 0.06 0.07 0.05 0.05 0.05
Valproic acid 777.6-2000 1514.16 1936.43 1170.70 1451.52 1342.35 849.64 1419.75 776.16
Vandetanib 0.039-60 2.60 6.85 9.36 21.08 8.68 15.17 6.69 9.56
IC50, half maximal inhibitory concentration.
that trichostatin A was the most active drug in all cell lines test-
ed. The least active drug was valproic acid (Table 3).
 When we pair the results of 4 drugs having similar cytotoxic 
mechanisms; quercetin and resveratrol which are derived from 
grape-polyphenols, and sunitinib and vandetanib as tyrosine 
kinase inhibitors; resveratrol and vandetanib showed lower IC50 
values than quercetin and sunitinib, respectively.
DISCUSSION
Patients with intractable thyroid carcinoma typically have an 
unfavorable prognosis (2), with refractory thyroid carcinoma 
having the most limited therapeutic options (9, 10). Recently, 
there have been studies of chemotherapy drugs to overcome 
such thyroid carcinomas (11). We therefore tested 20 chemo-
therapy and hormonal therapy drugs in 8 thyroid carcinoma 
cell lines, all of which originated from refractory thyroid carci-
nomas. We found that 5-FU, etoposide, methotrexate, and vin-
cristine showed favorable results in mean TIR each resulting in 
more than 30%. In addition, etoposide and vincristine had favor-
able mean index values for tumor growth inhibition. The previ-
ous studies focused on the combination chemotherapy indicat-
ed that doxorubicin, etoposide, paclitaxel, and vincristine were 
the most active drugs warranting further test (6, 7). In most of 
these studies, however, drugs were tested only against medul-
lary or anaplastic thyroid carcinomas (8). Fortunately, we yield 
a uniform result for etoposide and vincristine having favorable 
outcomes.
 Molecular targeted therapy and angiogenesis targeted thera-
pies are also being investigated in patients with refractory thyroid 
carcinomas (9, 15, 18). We found that trichostatin A had cyto-
toxic effect against refractory thyroid carcinoma cells. In another 
study, trichostatin A has been shown to increase the effect of 
RIA in advanced thyroid carcinomas (35). We also found that 
quercetin, resveratrol, sunitinib and vandetanib showed favor-
able results. Quercetin and resveratrol are grape-polyphenols 
that act as antioxidants, antiangiogenic agents and selective 
estrogen receptor modifiers. These drugs had beneficial effects 
in breast carcinomas and gynecologic diseases (36). Sunitinib 
and vandetanib are multi targeted receptor tyrosine kinase in-
hibitors. These drugs, which block the VEGF receptors, thereby 
inhibiting tumor angiogenesis and proliferation, are currently 
being investigated in patients with refractory thyroid carcino-
mas (15, 37, 38). Between the drugs having similar cytotoxic 
mechanisms, resveratrol and vandetanib were better than the 
counter drugs. In addition to these drugs, several other VEGF 
related drugs are being tested, including sorafenib (37), as well 
as tamoxifen, rosiglitazone and valproic acid (32, 39, 40). Unfor-
tunately, our study showed that cyclophosphamide and valproic 
acid were the least active drugs in tumor growth inhibition.
 The limitation of this study is that the cell lines were cultured 
and tested without the prior information about gene mutation 
differences such as BRAF or RAS. Also, such drugs were tested 
in in vitro study and the results may differ in in vivo study. The 
toxicity control in in vivo study will be a challenge as well. Also, 
selecting the patients to benefit from such therapy and decid-
ing the primary end point as either overall survival of progres-
sion-free survival of such application would be another dilem-
ma to solve. Further investigation of the above drugs and com-
bination test of the active drugs for their interaction effect should 
be continued for clinical application.
 In conclusion, etoposide, vincristine, trichostatin A, resvera-
trol, and vandetanib show prior favorable outcomes as the anti-
cancer drugs in thyroid carcinoma cell lines. These drugs may 
be used for an innovative therapy for refractory thyroid carcino-
mas.
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